

NO. 91494-R10

## BONE DENSITY STUDIES

Effective date: 12/01/2025

Last reviewed: 11/2025

**Instruction for use:** This document is for informational purposes only. Coverage is subject to member's specific benefits. Group specific policy will supersede this policy when applicable. Eligibility and benefit coverage are determined in accordance with the terms of the member's plan in effect as of the date services are rendered. It is not an authorization, certification, explanation of benefits, or contract. Receipt of benefits is subject to satisfaction of all terms and conditions of coverage. Priority Health's medical policies are developed with the assistance of medical professionals and are based upon a review of published and unpublished information including, but not limited to, current medical literature, guidelines published by public health and health research agencies, and community medical practices in the treatment and diagnosis of disease. Because medical practice, information, and technology are constantly changing, Priority Health reserves the right to review and update its medical policies at its discretion. Priority Health's medical policies are intended to serve as a resource to the plan. They are not intended to limit the plan's ability to interpret plan language as deemed appropriate. Physicians and other providers are solely responsible for all aspects of medical care and treatment, including the type, quality, and levels of care and treatment they choose to provide.

**Policy scope:** This policy addresses medical necessity criteria for bone mineral density (BMD).

---

### I. MEDICAL NECESSITY CRITERIA

- A. A one-time measurement of bone mineral density (BMD), using one method only, may be considered medically necessary to assess fracture risk and the need for pharmacologic therapy in the following patients considered at risk for osteoporosis, who are also considering treatment to prevent osteoporotic fracture
  - 1. All women aged 65 and older regardless of risk factors.
  - 2. Men or women with a fracture risk (10-year probability of fracture using  $FRAX \geq 9.3\%$ )
    - a. A [FRAX Assessment](#) is done to identify patients for BMD testing when any of the following criteria are met:
      - i. Personal history of fracture as an adult
      - ii. History of fragility fracture in a first degree relative
      - iii. Estrogen deficiency at an early age (<45 years)
      - iv. Current cigarette smoking
      - v. Low body weight (<127 lbs.)
      - vi. Alcohol 3 or more units per day
      - vii. Use of oral corticosteroid therapy for more than 3 months
      - viii. History of osteopenia or osteoporosis diagnosed via x-ray
      - ix. History of Depo-Provera® use
      - x. Individuals who are at increased risk for fractures due to diseases, conditions or treatments including, but not limited to primary hyperparathyroidism, renal failure (patients on

dialysis), decreased mineralization noted on other studies, lifelong low calcium intake, impaired vision, dementia, recent falls, low physical activity, poor health/frailty, use of aromatase inhibitor therapy, and long-term anti-convulsant therapy (e.g., phenytoin therapy).

3. Individuals beginning or on glucocorticoid therapy, provided intervention is an option. The most commonly used glucocorticoids include prednisone, prednisolone, betamethasone, dexamethasone, and decadron.
  4. Transplant patients.
  5. Men with hypogonadism or receiving androgen deprivation treatment.
- B. If the initial BMD measurement was medically necessary as defined above, serial measurements of BMD to monitor treatment response may be considered medically necessary when performed no more frequently than 24 months apart and when a change in treatment plan may be made based on BMD results. When the need for serial measurements is anticipated in high-risk patients who are likely to require treatment, and for obtaining serial measurements, a central DXA BMD measurement should be obtained.
- C. More frequent bone mass measurements may be considered medically necessary in any of the following circumstances:
1. Monitoring individuals on long-term glucocorticoid (steroid) therapy of more than 3 months duration; OR
  2. For a confirmatory baseline bone mass measurement to permit monitoring of individuals in the future if the initial bone mass test was performed with a technique that is different from the proposed testing method; or
  3. Monitoring of individuals with uncorrected primary hyperparathyroidism.
- D. A forearm DXA may be medically necessary when it is not feasible to obtain a central DXA.
- E. Peripheral DXA sites (wrist, fingers, heel, etc.) other than forearm DXA are not medically necessary as results from these tests are not comparable to central DXA.

## **II. CENTERS FOR MEDICARE & MEDICAID SERVICES (CMS) COVERAGE DETERMINATION**

Any applicable federal or state mandates will take precedence over this medical coverage policy.

Medicare: Refer to the [CMS Online Manual System \(IOMs\)](#) and Transmittals.

For the most current applicable CMS National Coverage Determination (NCD)/Local Coverage Determination (LCD)/Local Coverage Article (LCA) refer to [CMS Medicare Coverage Database](#).

The information below is current as of the review date for this policy. However, the coverage issues and policies maintained by CMS are updated and/or revised periodically. Therefore, the most current CMS information may not be contained in this document. MAC jurisdiction for purposes of local coverage determinations is governed by the geographic service area where the Medicare Advantage plan is contracted to provide the service. Please refer to the Medicare

[Coverage Database website](#) for the most current applicable NCD, LCD, LCA, and CMS Online Manual System/Transmittals.

National Coverage Determinations (NCDs)	
National Coverage Determinations (NCDs)	Bone (Mineral) Density Studies (NCD <a href="#">150.3</a> )
Local Coverage Determinations (LCDs)	
CGS Administrators, LLC	Bone Mass Measurement ( <a href="#">L36460</a> )
Palmetto GBA	Bone Mass Measurement (L39268)

## II. BACKGROUND

Osteoporosis, defined as low bone mass leading to an increased risk of fragility fractures, is an extremely common disease in the elderly due to age-related bone loss in both sexes and menopause-related bone loss in women. Current practice guidelines published by the Bone Health and Osteoporosis Foundation recommend that measurement of bone mineral density (BMD) be performed in all women over the age of 65 and in postmenopausal women with additional risk factors. Additional risk factors include a personal history of fracture as an adult, history of fracture in a first-degree relative, current cigarette smoking, and low body weight (<127 lbs). Patients receiving glucocorticoid therapy are also at risk for bone loss, no matter what the age. Therefore, BMD measurements are often performed prior to initiating therapy.

Bone mineral density (BMD) can be measured with a variety of techniques in a variety of sites. Sites are broadly subdivided into central sites (e.g., hip or spine) and peripheral sites (e.g., wrist, finger, heel). While BMD measurements are predictive of fragility fractures at all sites, central measurements of the hip and spine are the most predictive. Additionally, fractures of the hip and spine (e.g., vertebral fractures) are the most clinically relevant. The most commonly used techniques are Dual X-ray Absorptiometry (DXA), Quantitative computed tomography (QCT), and Ultrasound Densitometry. BMD is one of the key determinants of the need for pharmacologic therapy. BMD is typically expressed in terms of the number of standard deviations (SD) the BMD falls below the mean for young, healthy adults. This number is termed the T score. The NOF guidelines recommend that pharmacologic therapy be initiated in women with T scores  $\leq -2.5$  at the femoral neck, total hip, or lumbar spine by DXA and in postmenopausal women and men age 50 and older with low bone mass (T-score between  $-1.0$  and  $-2.5$ , osteopenia) at the femoral neck, total hip, or lumbar spine by DXA and a 10-year hip fracture probability  $\geq 3\%$  or a 10-year major osteoporosis-related fracture probability  $\geq 20\%$ . Current pharmacologic options include hormone replacement therapy, bisphosphonates such as alendronate (Fosamax), selective estrogen receptor modulators (SERMs) such as raloxifene (Evista), and calcitonin. While BMD measurements are typically used to determine the need for pharmacologic therapy, serial monitoring of BMD to determine treatment response is also performed.

Dual-energy x-ray absorptiometry (DXA) is considered the gold standard because it is the most extensively validated test against fracture outcomes. In general, a central DXA BMD measurement should be strongly considered for initial screening purposes due to its reproducibility and ability to simultaneously establish the diagnosis of osteoporosis and provide a baseline if one is needed. Biomechanical studies have shown a strong

correlation between mechanical strength and BMD measured by DXA. This approach is endorsed by the National Osteoporosis Foundation's Clinician's Guide to Prevention and Treatment of Osteoporosis as well as the Michigan Quality Improvement Consortium Guideline: Management and Prevention of Osteoporosis

When used in the same patients, DXA machines from different manufacturers differ in the proportion of patients diagnosed to have osteoporosis by 6 to 15 percent. Published studies consistently show that the probability of receiving a diagnosis of osteoporosis depends on the choice of test and site. One analytical study, for example, found that 6 percent of women older than 60 years of age would receive a diagnosis of osteoporosis if DXA of the total hip were used as the only test, compared with 14 percent for DXA of the lumbar spine, 3 percent with quantitative ultrasonography, and 50 percent with quantitative computed tomography (Faulker, 1999).

A meta-analysis assessed 23 publications from 11 separate prospective cohort studies published before 1996. Nearly all of the data were from women in their late 60s or older. No studies of ultrasonography were included. The meta-analysis indicated that DXA at the femoral neck predicted hip fracture better than measurements at other sites, and was comparable to forearm measurements for predicting fractures at other sites. For bone density measurements at the femoral neck, the pooled relative risk per decrease of one SD in bone density was 2.6 (CI, 2.0-3.5). In direct comparisons, heel ultrasonography was slightly worse than but comparable to DXA of the hip in women older than 65 years of age). For both tests, a result in the osteoporotic range is associated with an increased short-term probability of hip fracture. No data compare DXA and ultrasonography for prediction of fracture in women younger than 65 years of age.

### III. GUIDELINES / POSITION STATEMENTS

Medical/Professional Society	Guideline
Bone Health and Osteoporosis Foundation (BHOFF)	<a href="#">Clinician's Guide to Prevention and Treatment of Osteoporosis (2022)</a>
International Society for Clinical Densitometry	<a href="#">Indications for Bone Mineral Density (BMD) Testing (2019)</a>
U.S. Preventive Services Task Force	<a href="#">Osteoporosis to Prevent Fractures: Screening (2025)</a>

### IV. CODING

**ICD-10 Codes** that may apply:

E05.00 - E05.91	Thyrotoxicosis
E07.0	Hypersecretion of calcitonin
E20.1 – E20.9	Hypoparathyroidism
E21.1 – E21.5	Hyperparathyroidism and other disorders of parathyroid gland
E23.0	Hypopituitarism
E24.0 – E24.9	Cushing's syndrome
E28.310 - E28.39	Primary ovarian failure
E29.1	Testicular hypofunction
E34.2	Ectopic hormone secretion, not elsewhere classified
E43	Unspecified severe protein-calorie malnutrition

E44.0 – E44.1	Protein-calorie malnutrition
E45	Retarded development following protein-calorie malnutrition
E46	Unspecified protein-calorie malnutrition
E64.0	Sequelae of protein-calorie malnutrition
E83.50 - E83.59	Disorders of calcium metabolism
E89.40	Asymptomatic postprocedural ovarian failure
E89.41	Symptomatic postprocedural ovarian failure
K50.00 - K50.919	Crohn's disease
K51.00 – K51.919	Ulcerative colitis
K90.0 – K90.9	Intestinal malabsorption
K91.2	Postsurgical malabsorption, not elsewhere classified
M40.00 - M40.299	Kyphosis
M48.40xA – M48.48xS	Fatigue fracture of vertebra
M48.50xA – M48.58xS	Collapsed vertebra
M80.00xA - M80.88XS	Osteoporosis with current pathological fracture
M81.0 – M81.8	Osteoporosis without current pathological fracture
M83.0 – M83.9	Adult osteomalacia
M84.30xA – M84.9	Disorder of continuity of bone
M85.80 – M85.9	Disorder of bone density and structure
M89.9	Disorder of bone, unspecified
M94.9	Disorder of cartilage, unspecified
N18.1 – N18.9	Chronic kidney disease
N25.0 – N25.9	Disorders resulting from impaired renal tubular function
N91.0 – N91.5	Absent, scanty and rare menstruation
N95.0 – N95.9	Menopausal and other perimenopausal disorders
Q61.00 – Q61.9	Cystic kidney disease
Q96.0 – Q96.9	Turner's syndrome
R29.890	Loss of height
S12.000A - S12.9xxS	Fracture of cervical vertebra and other parts of neck
S14.101A – S14.9xxS	Injury of nerves and spinal cord at neck level
S22.000A - S22.089S	Fracture of thoracic vertebra
S24.101A – S24.159S	Other and unspecified injuries of thoracic spinal cord
S32.000A - S32.2xxS	Fracture of lumbar spine
S34.101A - S34.3xxS	Injury of lumbar and sacral spinal cord
S72.001A - S72.26XS	Fracture of neck of right femur
S79.001A - S79.099S	Physeal fracture of upper end of femur
T38.0x1A – T38.0x5S	Poisoning by, adverse effect of and under dosing of glucocorticoids and synthetic analogues
Z08	Encounter for follow-up examination after completed treatment for malignant neoplasm
Z09	Encounter for follow-up examination after completed treatment for conditions other than malignant neoplasm
Z40.02	Encounter for prophylactic removal of ovary
Z78.0	Asymptomatic menopausal state
Z79.3	Long term (current) use of hormonal contraceptives
Z79.51	Long term (current) use of inhaled steroids
Z79.52	Long term (current) use of systemic steroids
Z79.891	Long term (current) use of opiate analgesic
Z79.899	Other long term (current) drug therapy
Z90.721	Acquired absence of ovaries, unilateral
Z90.722	Acquired absence of ovaries, bilateral

Z90.79 Acquired absence of other genital organ(s)

**ICD-10 Diagnoses** that support screening central DEXA (77080, 77085) for female commercial members:

Z00.00 Encounter for general adult medical examination without abnormal findings  
Z00.01 Encounter for general adult medical examination with abnormal findings  
Z13.820 Encounter for screening for osteoporosis  
Z78.0 Asymptomatic menopausal state

**ICD-10 Diagnoses** that support peripheral DEXA (77081) for female commercial members:

M85.831 Other specified disorders of bone density and structure, right forearm  
M85.832 Other specified disorders of bone density and structure, left forearm

### **CPT/HCPCS Codes**

*No Prior Authorization required:*

77080 Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (e.g., hips, pelvis, spine)  
77081 Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel) *(Covered for Medicare only) For Commercial and Medicaid when 77080 cannot be performed for the forearm only.*  
77085 Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (e.g., hips, pelvis, spine), including vertebral fracture assessment  
77086 Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA)  
G0130 Single energy x-ray absorptiometry (SEXA) bone density study, one or more sites; appendicular skeleton (peripheral) (e.g., radius, wrist, heel) *(Covered for Medicare and Medicaid only)*  
76977 Ultrasound bone density measurement and interpretation, peripheral site(s), any method

Pre-authorization required:

**Note: eviCore provides prior authorization medical necessity review services on behalf of Priority Health for participating providers. Prior authorization for out-of-network providers must be requested through Priority Health. Bone density studies may be covered when eviCore criteria are met.**

77078 Computed tomography, bone mineral density study, 1 or more sites; axial skeleton (e.g., hips, pelvis, spine)

Not covered:

0554T Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan;

- retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report (covered for Medicare only)
- 0555T Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data (covered for Medicare only)
- 0556T Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; assessment of bone strength and fracture risk and bone mineral density (covered for Medicare only)
- 0557T Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; interpretation and report (covered for Medicare only)
- 0691T Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report
- 0743T Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density, with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and bone mineral density and classification of any vertebral fractures, with overall fracture risk assessment, interpretation and report
- 0749T Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report;
- 0750T Bone strength and fracture-risk assessment using digital X-ray radiogrammetry-bone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report; with single-view digital X-ray examination of the hand taken for the purpose of DXR-BMD
- 0815T Ultrasound-based radiofrequency echographic multi-spectrometry (REMS), bone-density study and fracture-risk assessment, 1 or more sites, hips, pelvis, or spine
- 77089 Trabecular bone score (TBS), structural condition of the bone microarchitecture; using dual X-ray absorptiometry (DXA) or other imaging data on gray-scale variogram, calculation, with interpretation and report on fracture-risk
- 77090 Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical preparation and transmission of data for analysis to be performed elsewhere
- 77091 Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical calculation only
- 77092 Trabecular bone score (TBS), structural condition of the bone microarchitecture; interpretation and report on fracture-risk only by other qualified health care professional
- 78350 Bone density (bone mineral content) study, one or more sites; single photon absorptiometry
- 78351 Bone density (bone mineral content) study, one or more sites; dual photon absorptiometry, one or more sites

G0556 3d radiodensity-value bone imaging, algorithm derived, from previous magnetic resonance examination of the same anatomy (*Covered for Medicare*)

## V. MEDICAL NECESSITY REVIEW

Prior authorization for certain drug, devices, services and procedures may or may not be required. In cases where prior authorization is required, providers will submit a request demonstrating that a drug, service or procedure is medically necessary. For more information, refer to the [Priority Health Provider Manual](#).

## VI. APPLICATION TO PRODUCTS

Coverage is subject to the member's specific benefits. Group-specific policy will supersede this policy when applicable.

- **HMO/EPO:** This policy applies to insured HMO/EPO plans.
- **POS:** This policy applies to insured POS plans.
- **PPO:** This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.
- **ASO:** For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.
- **INDIVIDUAL:** For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.
- **MEDICARE:** Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, this policy applies.
- **MEDICAID/HEALTHY MICHIGAN PLAN:** For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the [Michigan Medicaid Fee Schedule](#). If there is a discrepancy between this policy and the [Michigan Medicaid Provider Manual](#), the Michigan Medicaid Provider Manual will govern. If there is a discrepancy or lack of guidance in the Michigan Medicaid Provider Manual, the Priority Health contract with Michigan Medicaid will govern. For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.

## VII. REFERENCES

1. Ahmed AI, Blake GM, Rymer JM, Fogelman I. Screening for osteopenia and osteoporosis: do the accepted normal ranges lead to overdiagnosis? *Osteoporos Int* 1997;7:432-38.
2. American College of Radiology. ACR Appropriateness Criteria. Osteoporosis and Bone Mineral Density (Revised 2022). Available at <https://acsearch.acr.org/docs/69358/Narrative/> (Accessed October 5, 2023).
3. Arlot ME, Sornay-Rendu E, Garnero P, Vey-Marty B, Delmas PD. Apparent pre- and postmenopausal bone loss evaluated by DXA at different skeletal sites in women: the OFELY cohort. *J Bone Miner Res* 1997;12(4):683-90.
4. Black DM, Cummings SR, Genant HK, Nevitt MC, Palermo L, Browner W. Axial and appendicular bone density predict fractures in older women. *J Bone Miner Res* 1992;7(6):633-38.



5. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis – 2016. *Endocr Pract*. 2016 Sep 2;22(Suppl 4):1-42
6. Chen Z, Maricic M, Lund P, Tesser J, Gluck O. How the new Hologic hip normal reference values affect the densitometric diagnosis of osteoporosis. *Osteoporos Int* 1998;8:423-27.
7. Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, et al. Bone density at various sites for prediction of hip fractures. *Lancet* 1993;341:72-5.
8. Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, Lindsay R; National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. *Osteoporos Int*. 2014 Oct;25(10):2359-81. doi: 10.1007/s00198-014-2794-2. Epub 2014 Aug 15. Erratum in: *Osteoporos Int*. 2015 Jul;26(7):2045-7. PMID: 25182228; PMCID: PMC4176573.
9. Faulkner KG, von Stetten E, Miller P. Discordance in patient classification using T-scores. *J Clin Densitomet* 1999;2(3):343-50.
10. Grampp S, Henk CB, Fuerst TP, Lu Y, Bader TR, Kainberger F, et al. Diagnostic agreement of quantitative sonography of the calcaneus with dual X-ray absorptiometry of the spine and femur. *Am J Roentgenol* 1999;173(2):329-34.
11. International Society for Clinical Densitometry. 2019 ISCD Official Positions-Adult. Available @ <https://iscd.org/learn/official-positions/adult-positions/> (Retrieved October 5, 2021).
12. Kroger H, Lunt M, Reeve J, Dequeker J, Adams JE, Birkenhager JC, et al. Bone density reduction in various measurement sites in men and women with osteoporotic fractures of spine and hip: the European quantitation of osteoporosis study. *Calcif Tissue Int* 1999;64(3):191-9.
13. Laskey M, Crisp A, Cole T, Compston J. Comparison of the effect of different reference data on Lunar DPX and Hologic QDR-1000 dual-energy X-ray absorptiometers. *Br J Radiol* 1992;65(780):1124-29.
14. LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES. The clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int*. 2022 Oct;33(10):2049-2102. doi: 10.1007/s00198-021-05900-y. Epub 2022 Apr 28. Erratum in: *Osteoporos Int*. 2022 Jul 28;: PMID: 35478046; PMCID: PMC9546973.
15. Lunt M, Felsenberg D, Reeve J, Benevolenskaya L, Cannata J, Dequeker J, et al. Bone density variation and its effects on risk of vertebral deformity in men and women studied in thirteen European centers: the EVOS Study. *J Bone Miner Res* 1997;12(11):1883-94.
16. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. *BMJ* 1996; 312:1254-59.
17. Melton LJ, Atkinson E, O'Fallon W, Wahner H, Riggs B. Long-term fracture prediction by bone mineral assessed at different skeletal sites. *J Bone Miner Res* 1993;8(10):1227-33.

18. Michigan Association of Health Plans. Michigan Quality Improvement Consortium Guideline. Management and Prevention of Osteoporosis. Available @ <https://www.mahp.org/michigan-quality-improvement-consortium> (Retrieved September 8, 2025).
19. Petley GW, Cotton AM, Murrills AJ, Taylor PA, Cooper C, Cawley MI, et al. Reference ranges of bone mineral density for women in southern England: the impact of local data on the diagnosis of osteoporosis. Br J Radiol 1996;69(823):655-60.
20. Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR, Rosen HN, Weber DR, Zemel BS, Shepherd JA. Executive Summary of the 2019 ISCD Position Development Conference on Monitoring Treatment, DXA Cross-calibration and Least Significant Change, Spinal Cord Injury, Peri-prosthetic and Orthopedic Bone Health, Transgender Medicine, and Pediatrics. J Clin Densitom. 2019 Oct-Dec;22(4):453-471. doi: 10.1016/j.jocd.2019.07.001. Epub 2019 Jul 5. PMID: 31400968.
21. Simmons A, Barrington S, O'Doherty MJ, Coakley AJ. Dual energy X-ray absorptiometry normal reference range use within the UK and the effect of different normal ranges on the assessment of bone density. Br J Radiol 1995;68(812):903-9.
22. Varney LF, Parker RA, Vincelette A, Greenspan SL. Classification of osteoporosis and osteopenia in postmenopausal women is dependent on site-specific analysis. J Clin Densitomet 1999;2(3):275-83.

---

**Past review dates:** 01/05, 12/05, 12/06, 12/07, 12/08, 10/09, 10/10, 10/11, 10/12, 10/13, 8/14, 8/15, 8/16, 8/17, 8/18, 8/19, 11/19, 11/20, 11/21, 11/22, 11/23, 11/24

*AMA CPT Copyright Statement: All Current Procedure Terminology (CPT) codes, descriptions, and other data are copyrighted by the American Medical Association.*

*The name "Priority Health" and the term "plan" mean Priority Health, Priority Health Managed Benefits, Inc., Priority Health Insurance Company and Priority Health Government Programs, Inc.*